EFFECTS OF CHINA-MADE RECOMBINANT HUMAN GROWTH HORMONE ON THE TREATMENT OF GROWTH HORMONE DEFICIENCY

Objective To evaluate the therapeutic effect of China-made recombinant human growth hormone (r-hGH) in children with growth hormone deficiency (GHD) and to investigate the utilities of various biochemical parameters in GHD diagnosis and treatment.Methods Our study comprises of 30 normal children and 71 GHD children treated with China-made r-hGH substitution 3 (IGFBP-3), bone turnover markers (Ost, ICTP), and anti-growth hormone antibody (GHAb) were detected before and after r-hGH treatment.Results After the first 3 and 6 months of treatment, growth velocities of GHD children were significantly increased (13.1 3.7 and 12.6 ± 3.6 cm/year) compared with pretreatment values (2.9 ± 0.8 cm/year, P ＜ 0.01). GHD Children had obviously reduced serum levels of IGF-1, IGFBP-3, and bone turnover markers (Ost, ICTP) compared with normal controls(P ＜ 0.01), and these biochemical parameters improved significantly after treatment (P ＜ 0.01). Growth hormone antibodies were positive in 17 of 45 cases after treatment by binding capacity detection. The binding percentage of growth hormone antibody which was increased more than 30% after the treatment showed a negative correlation with growth velocity (P ＜ 0.01).Conclusions (1) The growth stimulating effect and safety were confirmed in using China-made r-hGH in the treatment of GHD children for 6 months. (2) The measurements of serum IGF-1 and IGFBP-3 may serve as useful parameters in the diagnosis of GHD. (3) Serum Ost and ICTP are useful laboratory criteria for evaluating the effect of r-hGH therapy in the early stage. (4) It is necessary to monitor serum levels of GHAb during r-hGH therapy.     

Preliminary report on various symptoms of chronic hepatitis treated with radix Astragali and its regulative effect on levels of serum hormone

67 cases of chronic hepatitis were treated with Radix Astragali. After treatment (2-month course), the clinical improvement rates in 38 cases of the Gan-Yu Pi-Xu type and in 26 cases of the Gan-Shen Yin-Xu type were 92.1% and 88.5% respectively, more effective than that of the control group (P less than 0.05). The regulative effect to the levels of serum hormone was observed in the patients of Gan-Yu Pi-Xu type with this medicine. The results showed that the levels of serum T3, E2 (female) and T (male) were increased after treatment (1.40 +/- 1.38 ng/dl, 129.30 +/- 1.23 pg/ml and 496.24 +/- 1.47 ng/dl respectively) than that before treatment (1.22 +/- 1.49 ng/dl, 104.60 +/- 1.45 pg/ml and 398.17 +/- 1.55 ng/dl respectively, P less than 0.05); however, the level of serum PRL (2.75 +/- 4.46 ng/ml) was lower after treatment than that (3.20 +/- 3.82 ng/ml) before treatment (P less than 0.05). No obvious changes were observed in the levels of serum FSH, LH, TSH, T4; T3U and F after treatment.     

Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height

The long-acting analogue of luteinizing hormone releasing hormone, D-Trp6-Pro9-NEt-LHRH (LHRHa), is effective in the short-term treatment of central precocious puberty. We report the results of two to four years of LHRHa therapy in 27 children with this disorder. Secondary sex characteristics regressed in most patients. Sex steroid levels and basal and LHRH-stimulated gonadotropin levels remained suppressed compared with pretreatment values. Linear growth rates decreased from 11.0 +/- 0.8 (SEM) cm/yr before treatment to 5.7 +/- 0.4 cm/yr at two years of treatment and 3.7 +/- 0.7 cm/yr at four years of treatment. Predicted heights by the Bayley-Pinneau method increased from 156.4 +/- 2.0 cm before treatment to 162.3 +/- 2.3 cm at two years and 163.4 +/- 2.4 cm at three years. Five patients treated for four years had a mean increase in predicted height of 5.5 cm. To date no adverse effects have been observed. However, the ultimate safety of this analogue is not known. We conclude that LHRHa appears to be an effective long-term therapy for central precocious puberty.     

长效促性腺激素类似物治疗女童特发性中枢性性早熟的疗效

目的观察长效促性腺激素类似物(GnRHa)治疗女童特发性中枢性性早熟(ICPP)的疗效和副作用.方法对36例ICPP女童进行GnRHa治疗,观察治疗前后第二性征、子宫容积、卵巢容积、卵泡发育、骨龄与年龄比值(BA/CA)、体块指数(BMI)和生长速率的变化,采用Greulich-Pyle法评价骨龄,用Payley-Pinneau法预测成年预测身高(PAH),ELISA法测定血清抑制素A(INHA)和抑制素B(INHB),用化学发光法测定血清LH和FSH.结果①治疗3～6个月乳房均有缩小,其中12例Tanner Ⅱ期的女童治疗6个月乳房恢复到B1期;②治疗6个月子宫容积[(3.28±2.20)ml vs (1.27±0.69)ml]和卵巢容积[(3.62±1.94)ml vs (1.24±0.50)ml]均缩小,卵泡缩小甚至消失;血清INHA和INHB由治疗前Log(0.93±0.35)ng/L、Log(1.95±0.37)ng/L下降到Log(0.60±0.32)ng/L、Log(1.46±0.32)ng/L.③治疗1年,BA/CA由治疗前1.40±0.20下降到1.26±0.15;PAH由(149.12±4.04)cm升高到(152.84±3.72)cm,BMI治疗前后无明显变化(16.04±1.68 vs 15.93±1.69).结论GnRHa治疗能有效抑制性腺轴及第二性征的发育,延缓骨龄的成熟,改善预测成人身高,短期应用未见明显副作用.     

Changes in serum leptin levels during r-hGH treatment in growth hormone-deficient children

Leptin isa protein hormone which consistsof1 6 7amino acids,which is synthesized and secreted byadipocytes under the modulation and control of obgenes.Its main function is to balance the energyintake againstexpenditure of body.Recently,a directhormonal modulation of circulating leptin levels hasbeen suggested.Hormoneswith metaboliceffects suchas insulin,cortisol and thyroxine have been identifiedas possible regulators of leptin expression and thecomplex interplay of them in the modulation of l…     

Growth-promoting effect of recombinant human growth hormone and stanozolol in girls with Turner syndrome

ＳｉｎｃｅｔｈｅｔｗｏｃｌｉｎｉｃａｌｈａｌｍａｒｋｓｏｆＴｕｒｎｅｒｓｙｎｄｒｏｍｅａｒｅｒｅｔａｒｄｅｄｓｅｘｕａｌｄｅｖｅｌ－ｏｐｍｅｎｔａｎｄｓｈｏｒｔｓｔａｔｕｒｅ,ｉｔｉｓｎｅｃｅｓｓａｒｙｔｏｉｍｐｒｏｖｅｔｈｅｐｓｙｃｈｏｓｏｍａｔｉ...     

雌孕激素替代治疗对特纳综合征患者骨密度的影响

对8例特纳综合征患者进行6年的雌孕激素补充治疗,比较治疗前后骨密度的变化。治疗前患者的骨密度明显低于同龄同性别的正常水平。经过6年性激素治疗后,患者的骨密度略有增加,但仍显著低于同龄同性别的正常水平。第2～4腰椎的骨密度从（0．75±0．12）g／cm^2增加到（0．84±0．22）g／cm^2,同龄同性别的z评分从-3．2±0．9升高到-2．2±0．6。髋部总体的骨密度从（0．68±0．07）g/cm^2增加到（0．81±0．08）g／cm^2,Z评分从-2．2±0．5增加到-1．2±0．3。长期雌孕激素补充治疗,可改善特纳综合征患者的骨密度,但不能使骨密度恢复到正常水平。     

充血性心力衰竭患者甲状腺激素水平及临床意义

目的　探讨充血性心力衰竭 (CHF)患者血清甲状腺激素 (TH)的变化及临床意义。方法　用放射免疫法测定 30例CHF患者及 30例健康对照者血清三碘甲状腺原氨酸 (T3)、四碘甲状腺素 (T4 )、促甲状腺激素(TSH)水平。结果　CHF患者血清T3、T4 、TSH水平分别为 0 .8± 0 .2 8ng/ml、82 .2 1± 14.82ng/ml、5 .45± 2 .0 6mIU/L ,其中T3、T4 水平明显低于对照组 (P <0 .0 1,P <0 .0 5 ) ;治疗后分别为 1.38± 0 .30ng/ml、95 .34± 15 .82ng/ml、5 .35± 3 .10mIU/L ,T3、T4 增高与治疗前比较有显著性差异 (P <0 .0 1,P <0 .0 5 )。结论　CHF患者体内T3、T4 水平下降 ,且与CHF病情呈负相关 ,观察TH水平变化对判断CHF患者的病情、疗效及预后有一定临床意义。     

Recombinant DNA produced somatropin in the treatment of prepubertal growth hormone deficient children.

The safety and efficacy of recombinant DNA produced human growth hormone in the treatment of growth failure in prepubertal children with idiopathic or organic deficiency of pituitary GH has been assessed. Five patients entered this clinical trial. They had never been treated with hGH, anabolic steroids or any medicine that affected GH and all of them were healthy without any chronic disease; except patient 1, who took a surgical operation for cerebellar astrocytoma at the age of 3. Each patient was treated with subcutaneous injection of recombinant somatropin (SAIZEN) at a dosage of 0.2 IU/Kg +/- 10% three times per week in the evening for 1 year. Typical catch up growth was observed. The height increased by between 6.3 and 15.1 cm and their mean growth velocity of 3.7 cm/yr prior to therapy increased to 11.1 cm/yr during one year of treatment. The annual change in bone age during the treatment with SAIZEN was 2.0 +/- 0.6 years in four patients, except patient 2 who showed different bone age (right hand 3.5 years, left hand 6.0 years). Anti-hGH antibodies were observed in patient 1, but the binding capacity was low (1:10), and no clinical symptoms or growth attenuation occurred. No side effects or laboratory abnormalities were noted throughout the clinical trial. In conclusion, recombinant somatropin has a growth promoting effect and low immunogenicity, and it is shown to be safe and effective during the first year of therapy in children with GH deficiency.     

胰岛素治疗2型糖尿病患者甲状腺激素水平与抑郁情绪的相关性研究

目的 观察胰岛素强化治疗前后糖尿病患者抑郁情绪变化及与血清甲状腺激素水平的相关性.方法 选择340例2型糖尿病患者(T2DM),其中187例给予胰岛素强化治疗3个月,153例给予口服降糖药治疗,对入选患者治疗前后进行抑郁测定,化验其血糖、糖化血红蛋白(HbA1c)、血清甲状腺激素,并进行统计学处理.治疗期间空腹血糖(FPG)控制在4.4mmol/L～6.1 mmol/L,餐后2 h血糖(2hPG)控制在4.4mmoL/L～8.0mmol/L之间.结果 胰岛素治疗前合并抑郁情绪的糖尿病患者甲状腺激素水平[分别为:甲状腺素(T4)(6.1±1.4)μg/dl,三碘甲状腺原氨酸(T3)(0.98±0.26)ng/m1]均低于无抑郁情绪的患者[T4(8.4±1.7)μg/dl,T3(1.51±0.29)ng/ml](P＜0.01),促甲状腺激素(TSH)水平[(4.5±1.1)uIU/m1]高于无抑邰情绪者[(1.9±0.9)uIU/ml](P＜0.01);胰岛素治疗后合并抑邰情绪的患者抑郁指数为(0.51±0.12)较治疗前明显降低(0.68±0.21)(P＜0.01),T3、T4水平明显升高[分别为:T3(1.38±0.28)ng/ml,T4(7.7±1.5)μg/dl](P＜0.01),TSH水平明显降低[(2.1±1.2)uIU/ml](P＜0.01).治疗前抑郁指数与T4、T3呈负相关(r=-0.468、-0.511,P＜0.05),与TSH呈正相关(r=0.583,P＜0.01);胰岛素组治疗后抑郁指数下降与T3、T4升高呈显著正相关(r=0.395、0.337,P＜0.05),与TSH下降呈负相关(r=-0.239,P＜0.05),而口服降糖药组治疗前后抑郁指数及甲状腺激素水平无明显变化.结论 胰岛素治疗后2型糖尿病患者抑郁情绪的改善与甲状腺激素水平相关.

Abstract：

Objective To observe the correlation of mood changes and serum levels of thyroid hormone in patients with diabetes and depression mood before and after intensive insulin therapy. Methods 340 patients with type 2 diabetes (T2DM) were enrolled, of which 187 cases were given intensive insulin therapy for 3 months and the other 153 cases were treated with oral hypoglycemic. All patients received depression measurement and tests of blood glucose, glycated hemoglobin (HbA1c), serum thyroid hormones before and after treatment. The data were analyzed statistically. During the treatment, fasting plasma glucose was controlled in ( 4.4 ～ 6. 1 )mmoL/L and 2-hour postprandial plasma glucose was controlled in (4.4 ～ 8.0) mmol/L. Results Thyroid hormone levels in the diabetic patients with depression mood ( T4 ( 6. 1 ± 1.4 ) μg/dl, T3 ( 0.98 ± 0.26) ng/ml ) were all lower than that in without depression mood ( T4 ( 8.4 ± 1.7 ) μg/dl, T3 ( 1.51 ± 0.29 ) ng/ml ) (P ＜ 0. 01 ), and TSH ( 4.5 ± 1. 1 ) were higher than that in without depression mood ( 1.9 ± 0.9 ) uIU/ml (P ＜ 0.01 ) before insulin treatment. After insulin therapy depression degree( 0.51 ± 0.12) were decreased significantly (0.68 ± 0. 21 )(P＜0.01 ) ,and thyroid hormone levels were significantly increased (T3 (1.38 ± 0. 28 )ng/ml,T4 (7.7 ±1.5 )μg/dl ),and TSH levels were significantly reduced( (2.1 ± 1.2 ) uIU/ml) (P ＜ 0. 01 ) than that before insulin therapy in the patients combined with depression mood. Depression degree was significantly negative correlated with T4 and T3 ( r= - 0.468, - 0.511, P ＜ 0.05 ) and significantly positive correlated with TSH ( r = 0.583, P＜ 0.01 ) before treatment. Decline of depression degree were significantly positive correlated with elevation of T3, T4 levels ( r =0. 395 ,0. 337, P＜0. 05 ) and were significantly negative correlated with decrease of TSH levels( r= -0. 239, P＜0.05 ) after insulin treatment. However, depression degree and thyroid hormone levels did not significantly change before and after in oral antihyperglycemic agents groups. Conclusion Improvement of depression was associated with thyroid hormone levels in type 2 diabetic patients after insulin therapy.